286 related articles for article (PubMed ID: 23554961)
21. Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer.
Lee SJ; Yeo JS; Lee HJ; Lee EJ; Kim SY; Jang SJ; Lee JJ; Ryu JS; Moon DH
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1327-35. PubMed ID: 24562648
[TBL] [Abstract][Full Text] [Related]
22. Preliminary
Ko IO; Jung KH; Kim MH; Kang KJ; Lee KC; Kim KM; Noh I; Lee YJ; Lim SM; Kim JY; Park JA
Contrast Media Mol Imaging; 2017; 2017():3981358. PubMed ID: 29097919
[TBL] [Abstract][Full Text] [Related]
23. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
[TBL] [Abstract][Full Text] [Related]
24. Increase of [(18)F]FLT tumor uptake in vivo mediated by FdUrd: toward improving cell proliferation positron emission tomography.
Viertl D; Bischof Delaloye A; Lanz B; Poitry-Yamate C; Gruetter R; Mlynarik V; Ametamey SM; Ross TL; Lehr HA; André PA; Perillo-Adamer F; Kosinski M; Dupertuis YM; Buchegger F
Mol Imaging Biol; 2011 Apr; 13(2):321-31. PubMed ID: 20556524
[TBL] [Abstract][Full Text] [Related]
25. [18F]FLT-PET to predict pharmacodynamic and clinical response to cetuximab therapy in Ménétrier's disease.
McKinley ET; Smith RA; Tanksley JP; Washington MK; Walker R; Coffey RJ; Manning HC
Ann Nucl Med; 2012 Nov; 26(9):757-63. PubMed ID: 22821337
[TBL] [Abstract][Full Text] [Related]
26. Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'-
Schelhaas S; Wachsmuth L; Hermann S; Rieder N; Heller A; Heinzmann K; Honess DJ; Smith DM; Fricke IB; Just N; Doblas S; Sinkus R; Döring C; Schäfers KP; Griffiths JR; Faber C; Schneider R; Aboagye EO; Jacobs AH
J Nucl Med; 2018 Jul; 59(7):1063-1069. PubMed ID: 29476002
[TBL] [Abstract][Full Text] [Related]
27. Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3'-deoxy-3'-[¹⁸F]fluorothymidine in preclinical tumor models.
Lee SJ; Kang HY; Kim SY; Chung JH; Oh SJ; Ryu JS; Kim SB; Kang JS; Park SK; Kim HM; Kim MH; Moon DH
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1436-48. PubMed ID: 21484374
[TBL] [Abstract][Full Text] [Related]
28. Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.
Bradbury MS; Hambardzumyan D; Zanzonico PB; Schwartz J; Cai S; Burnazi EM; Longo V; Larson SM; Holland EC
J Nucl Med; 2008 Mar; 49(3):422-9. PubMed ID: 18287265
[TBL] [Abstract][Full Text] [Related]
29. Response Monitoring with [
Heskamp S; Heijmen L; Gerrits D; Molkenboer-Kuenen JDM; Ter Voert EGW; Heinzmann K; Honess DJ; Smith DM; Griffiths JR; Doblas S; Sinkus R; Laverman P; Oyen WJG; Heerschap A; Boerman OC
Mol Imaging Biol; 2017 Aug; 19(4):540-549. PubMed ID: 27798786
[TBL] [Abstract][Full Text] [Related]
30. 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging of thymidine kinase 1 activity after 5-fluorouracil treatment in a mouse tumor model.
Hong IK; Kim SY; Chung JH; Lee SJ; Oh SJ; Lee SJ; Oh J; Ryu JS; Kim TW; Kim DY; Moon DH
Anticancer Res; 2014 Feb; 34(2):759-66. PubMed ID: 24511010
[TBL] [Abstract][Full Text] [Related]
31. 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease.
Wagner M; Seitz U; Buck A; Neumaier B; Schultheiss S; Bangerter M; Bommer M; Leithäuser F; Wawra E; Munzert G; Reske SN
Cancer Res; 2003 May; 63(10):2681-7. PubMed ID: 12750297
[TBL] [Abstract][Full Text] [Related]
32. Sex as a Biologic Variable in Preclinical Imaging Research: Initial Observations with
Chan SR; Salem K; Jeffery J; Powers GL; Yan Y; Shoghi KI; Mahajan AM; Fowler AM
J Nucl Med; 2018 May; 59(5):833-838. PubMed ID: 29217733
[TBL] [Abstract][Full Text] [Related]
33. [Is 3'-deoxy-3'- [18F] fluorothymidine ([18F]-FLT) the next tracer for routine clinical PET after R [18F]-FDG?].
Couturier O; Leost F; Campone M; Carlier T; Chatal JF; Hustinx R
Bull Cancer; 2005 Sep; 92(9):789-98. PubMed ID: 16203269
[TBL] [Abstract][Full Text] [Related]
34. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
[TBL] [Abstract][Full Text] [Related]
35. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation.
Barwick T; Bencherif B; Mountz JM; Avril N
Nucl Med Commun; 2009 Dec; 30(12):908-17. PubMed ID: 19794320
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of [
Rapic S; Vangestel C; Verhaeghe J; Thomae D; Pauwels P; Van den Wyngaert T; Staelens S; Stroobants S
Mol Imaging Biol; 2017 Feb; 19(1):109-119. PubMed ID: 27324368
[TBL] [Abstract][Full Text] [Related]
37. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models.
Apisarnthanarax S; Alauddin MM; Mourtada F; Ariga H; Raju U; Mawlawi O; Han D; Bornmann WG; Ajani JA; Milas L; Gelovani JG; Chao KS
Clin Cancer Res; 2006 Aug; 12(15):4590-7. PubMed ID: 16899606
[TBL] [Abstract][Full Text] [Related]
38. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
Ullrich RT; Zander T; Neumaier B; Koker M; Shimamura T; Waerzeggers Y; Borgman CL; Tawadros S; Li H; Sos ML; Backes H; Shapiro GI; Wolf J; Jacobs AH; Thomas RK; Winkeler A
PLoS One; 2008; 3(12):e3908. PubMed ID: 19079597
[TBL] [Abstract][Full Text] [Related]
39. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
[TBL] [Abstract][Full Text] [Related]
40. The uptake of 3'-deoxy-3'-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels.
Barthel H; Perumal M; Latigo J; He Q; Brady F; Luthra SK; Price PM; Aboagye EO
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):257-63. PubMed ID: 15791434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
